1,10-phenanthroline has been researched along with Osteosarcoma in 2 studies
1,10-phenanthroline: RN given refers to parent cpd; inhibits Zn-dependent metalloproteinases
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| León, IE | 1 |
| Etcheverry, SB | 1 |
| Parajón-Costa, BS | 1 |
| Baran, EJ | 1 |
| Farley, JR | 1 |
| Magnusson, P | 1 |
2 other studies available for 1,10-phenanthroline and Osteosarcoma
| Article | Year |
|---|---|
Spectroscopic characterization of an oxovanadium(IV) complex of oxodiacetic acid and o-phenanthroline. Bioactivity on osteoblast-like cells in culture.
Topics: Acetates; Animals; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Rel | 2012 |
Effects of tunicamycin, mannosamine, and other inhibitors of glycoprotein processing on skeletal alkaline phosphatase in human osteoblast-like cells.
Topics: Alkaline Phosphatase; Anti-Bacterial Agents; Apoptosis; Bone and Bones; Cell Proliferation; Dose-Res | 2005 |